ULuvox CR ligama le-brandic generic fluvoxamine. I-Luvox yonyango lonyango elisetyenziselwa ukunyanga uxinzelelo , ingxaki yokunyanzelisa, kunye nezinye izimo zempilo yengqondo. Yenziwe ngeJazz Pharmaceuticals, uLuvox CR yavunywa yi-Food and Drug Administration ukunyangwa kwengxaki yokuxhalabisa abantu (SAD) ngoFebruwari 2008.
I-Luvox CR yinguqulo ekhutshwe ngokukhululeka yaseLuvox. I -serotonin i-reuptake inhibitor (SSRI) ekhethiweyo , i-Luvox CR iyancipha ukubuyisela kwakhona i-serotonin yekhemikhali kwingqondo. I-Serotonin ikholelwa ukuba idlala indima ekulawuleni imizwelo kunye nokuxhalabisa.
Indlela yokuthatha uLuvox CR
I-Luvox CR ivela kwifomu yethebhulethi kwaye kufuneka igonywe ngokupheleleyo. Kufuneka kuthathwe kanye ngosuku ngemini, kunye okanye ngaphandle kokutya. Ukuba uyakhohlwa ukuthatha umthamo wansuku zonke, thabatha xa ukhumbule. Nangona kunjalo xa ku futshane nexesha lakho elizayo, kulunge ukweqa idosi ephosakeleyo.
Kubalulekile ukuqhubeka nokuthatha uLuvox CR kade ugqirha wakho ufundisa, nokuba uqala ukuziva ungcono. Ukuba unokuyeka ngokukhawuleza ukuthatha i-Luvox CR, unakho ukufumana ukuphazamiseka kweempawu ezifana neentlanzi, ukungazinzi, ukuxhalaba kunye nesisu. Ukuze ugweme le miqondiso, ugqirha wakho uya kufuthula ngokukhawuleza umlinganiselo wakho xa uyeka ukuthatha uLvovox CR.
Izikhokelo zeNqanaba
Kwabantu abane-SAD, i-dosage ye-Luvox CR iqala ngo-100 mg ngosuku, ngokunyuka kwama-50 mg ngeveki ukuya kwi-300 mg.
Ngokubanzi, ukunyuswa kwamayeza kuya kuhamba ngokugqithiseleyo kwizigulane ezigugile.
Ngubani ongafanelanga ukuthatha uLuvox CR
ULuvox CR kufuneka isetyenziswe ngokuqaphela ukuba:
- i-hypersensitive to fluvoxamine maleate
- unembali yokubamba
- unembali ye-mania
- ukhulelwe okanye uceba ukukhulelwa
- ba ncelisa
Ukuphumelela kwe-Luvox CR kubantwana kunye nabaselula abazange bafundwe, kwaye amayeza ayengavunyelwa ukunyangwa kwe-SAD kubantu abangaphantsi kweminyaka eyi-18 ubudala.
Kukho ubungqina bokubonisa ingozi eyingozi yokuzibulala nokuziphatha kwabo kubantwana abathatha uLvox CR.
Ukusebenzisana
I-Luvox akufanele ithathwe kunye kunye okanye kwiiveki zokuthatha i-Monoamine Oxidase Inhibitors (MAOIs); umphumo wale nhlanganisela ingaba yingozi. I-Luvox CR ayifanele idibaniswe ne-thioridazine, i-pimozide, i-alosetron, i-tizanidine kunye ne-ramelteon.
Ukulumka kufuneka kusetyenziswe xa kuthatha amanye amachiza kunye neLuvox CR, njengama-anticoagulants kunye ne-anti-inflammatories. Ukusetyenziswa kotywala akukwaziswa nangona kuthatha u-Luvox CR. Kumele uxelele ugqirha wakho kwanoma imaphi imithi egunyazisiweyo, amayeza angaphezulu kwamayeza okanye ezinye izinto ozithathayo okanye oceba ukuzenza.
Imiphumela
Imiphumo emibi yeLuvox CR ibandakanya ukukhwabanisa, ukulala, ubuthathaka, isifo sohudo, i-anorexia, ukugubhazela, ukujuluka, kunye nokungaxhatshazi ngokwesondo (njengokungaqhelekanga nokungafihli ukufikelela kwi-orgasm).
Xa uqala u-Luvox CR okanye xa utshintsha i-dosage, jonga iziphumo ezibi kakhulu ezinjenge-agitation, ubundlobongela, ukwesaba, ukuxhatshazeka okukhulu, kunye neengcinga zokuzibulala nokuziphatha. Ukuba ufumana enye yale mpawu, kubalulekile ukuxela oku ugqirha ngokukhawuleza.
Kwabanye abantu, uLuvox CR inokuphazamisa isigwebo, ukucinga, kunye nezakhono. Kubalulekile ukuba ungasebenzisi umatshini onobungozi, kuquka nemoto, ngaphandle kokuba uqinisekile ukuba uLuvox CR ayikuchaphazeli ngale ndlela.
Mngcipheko
Umngcipheko wokugqithisa kokufa kweLuxx CR uphantsi kakhulu. Iimpawu zokugqithisa ngokwezinto zibandakanya isicupunu, ukuhlanza, isifo sohudo, i-coma, i-hypokalemia, i-hypotension, ubunzima bokuphefumula, ukulala nokuphunga kwenhliziyo.
Xa zidibaniswe namanye amayeza, kukho umngcipheko we-serotonin syndrome, imeko enokubulawa. Iimpawu ze-serotonin syndrome ziquka ukuphazamiseka, ukudideka, ukujuluka, ukuvumba, ukucinga okungaqhelekanga, ukuxhamla kwemisipha kunye nentliziyo esheshayo.
Ezinye iinkxalabo
> Imithombo:
> Bezchlibnyk-Butler KZ, Jeffries, JJ, eds. Incwadi YesiKlinikhi yee-Psychotropic Drugs . I-Toronto, Canada: Hogrefe & Huber; 2003.
> Jazz Pharmaceuticals. Luvox CR: Ukuchaza ulwazi. 21 uEpreli 2008.